- Home
- EXK vs CVAC Comparison
EXK vs CVAC Comparison
Compare EXK & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- CVAC
- Stock Information
- Founded
- EXK 1981
- CVAC 2000
- Country
- EXK Canada
- CVAC Germany
- Employees
- EXK N/A
- CVAC N/A
- Industry
- EXK Precious Metals
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- EXK Basic Materials
- CVAC Health Care
- Exchange
- EXK Nasdaq
- CVAC Nasdaq
- Market Cap
- EXK 920.7M
- CVAC 818.8M
- IPO Year
- EXK N/A
- CVAC 2020
- Fundamental
- Price
- EXK $3.83
- CVAC $3.30
- Analyst Decision
- EXK Strong Buy
- CVAC Hold
- Analyst Count
- EXK 3
- CVAC 3
- Target Price
- EXK $6.75
- CVAC $10.00
- AVG Volume (30 Days)
- EXK 9.8M
- CVAC 656.5K
- Earning Date
- EXK 03-11-2025
- CVAC 11-12-2024
- Dividend Yield
- EXK N/A
- CVAC N/A
- EPS Growth
- EXK N/A
- CVAC N/A
- EPS
- EXK N/A
- CVAC N/A
- Revenue
- EXK $225,927,000.00
- CVAC $70,565,734.00
- Revenue This Year
- EXK $8.33
- CVAC $742.57
- Revenue Next Year
- EXK $60.97
- CVAC N/A
- P/E Ratio
- EXK N/A
- CVAC N/A
- Revenue Growth
- EXK N/A
- CVAC 75.11
- 52 Week Low
- EXK $1.42
- CVAC $2.22
- 52 Week High
- EXK $5.67
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- EXK 47.10
- CVAC 39.12
- Support Level
- EXK $3.90
- CVAC $3.53
- Resistance Level
- EXK $4.22
- CVAC $3.72
- Average True Range (ATR)
- EXK 0.22
- CVAC 0.18
- MACD
- EXK -0.00
- CVAC -0.06
- Stochastic Oscillator
- EXK 1.69
- CVAC 10.96
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The company has three producing silver-gold mines in Mexico: the Guanacevi Mine in Durango, the Bolanitos Mine in Guanajuato and the El Compas Mine in Zacatecas. It also has three exploration projects in northern Chile: Aida project, Paloma project and the Cerro Marquez project.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.